SHEDIR PHARMA GROUP S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.76 EUR | +2.17% |
|
+4.44% | -16.81% |
| 02/04 | Shedir Pharma, into 2023 with rising revenues; profit down single digits | AN |
| 29/03 | Shedir Pharma Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 80 | 43.54 | 53.72 | 42.63 | 51.4 |
| Enterprise Value (EV) 1 | 88.91 | 43.57 | 46.92 | 36.99 | 58.66 |
| P/E ratio | - | 11.1 x | 13.7 x | 7.2 x | 9.2 x |
| Yield | - | 5.77% | 2.77% | 4.69% | - |
| Capitalization / Revenue | 1.58 x | 1.01 x | 1.2 x | 0.8 x | 0.87 x |
| EV / Revenue | 1.75 x | 1.01 x | 1.05 x | 0.69 x | 0.99 x |
| EV / EBITDA | 11.4 x | 6.48 x | 6.65 x | 4.04 x | 5.39 x |
| EV / FCF | -49 x | 5.54 x | 5.32 x | 39.3 x | -5.93 x |
| FCF Yield | -2.04% | 18% | 18.8% | 2.54% | -16.9% |
| Price to Book | - | 1.63 x | 1.91 x | 1.3 x | 1.43 x |
| Nbr of stocks (in thousands) | 11,429 | 11,429 | 11,430 | 11,430 | 11,372 |
| Reference price 2 | 7.000 | 3.810 | 4.700 | 3.730 | 4.520 |
| Announcement Date | 14/04/20 | 15/04/21 | 14/04/22 | 13/04/23 | 12/04/24 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 46.89 | 50.69 | 43.15 | 44.82 | 53.48 | 59.39 |
| EBITDA 1 | 10.13 | 7.831 | 6.727 | 7.057 | 9.164 | 10.89 |
| EBIT 1 | 9.249 | 6.697 | 5.476 | 5.408 | 7.189 | 8.369 |
| Operating Margin | 19.72% | 13.21% | 12.69% | 12.06% | 13.44% | 14.09% |
| Earnings before Tax (EBT) 1 | 8.886 | 4.909 | 5.307 | 5.703 | 8.245 | 8.076 |
| Net income 1 | 6.367 | 2.838 | 3.926 | 3.925 | 5.925 | 5.699 |
| Net margin | 13.58% | 5.6% | 9.1% | 8.76% | 11.08% | 9.6% |
| EPS | - | - | 0.3435 | 0.3434 | 0.5184 | 0.4915 |
| Free Cash Flow 1 | 0.7081 | -1.815 | 7.858 | 8.818 | 0.9414 | -9.901 |
| FCF margin | 1.51% | -3.58% | 18.21% | 19.67% | 1.76% | -16.67% |
| FCF Conversion (EBITDA) | 6.99% | - | 116.82% | 124.95% | 10.27% | - |
| FCF Conversion (Net income) | 11.12% | - | 200.16% | 224.65% | 15.89% | - |
| Dividend per Share | - | - | 0.2200 | 0.1300 | 0.1750 | - |
| Announcement Date | 02/07/19 | 14/04/20 | 15/04/21 | 14/04/22 | 13/04/23 | 12/04/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 14.6 | 8.92 | 0.03 | - | - | 7.26 |
| Net Cash position 1 | - | - | - | 6.8 | 5.64 | - |
| Leverage (Debt/EBITDA) | 1.445 x | 1.138 x | 0.004757 x | - | - | 0.667 x |
| Free Cash Flow 1 | 0.71 | -1.81 | 7.86 | 8.82 | 0.94 | -9.9 |
| ROE (net income / shareholders' equity) | 70.9% | 11.7% | 16% | 14.3% | 19.5% | 16.6% |
| ROA (Net income/ Total Assets) | 14.2% | 7.76% | 6.81% | 6.42% | 8.22% | 9.27% |
| Assets 1 | 44.97 | 36.58 | 57.68 | 61.17 | 72.11 | 61.51 |
| Book Value Per Share | - | - | 2.330 | 2.460 | 2.870 | 3.170 |
| Cash Flow per Share | - | - | 1.440 | 1.670 | 1.380 | 0.1100 |
| Capex | - | 0.47 | 0.27 | 1.18 | 0.43 | 3.61 |
| Capex / Sales | - | 0.93% | 0.63% | 2.64% | 0.8% | 6.07% |
| Announcement Date | 02/07/19 | 14/04/20 | 15/04/21 | 14/04/22 | 13/04/23 | 12/04/24 |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.68
EUR
Average target price
8.08
EUR
Spread / Average Target
+119.57%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.81% | 45.04M | |
| +29.62% | 662B | |
| +21.96% | 546B | |
| -5.53% | 359B | |
| +16.45% | 323B | |
| +4.41% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.52% | 167B |
- Stock Market
- Equities
- SHE Stock
- Financials Shedir Pharma Group S.p.A.